Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unnus
- Development stage
- Unknown
- Lead developer
- Industria Farmacéutica Andrómaco
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
UNNUS (also marketed as UNNUS 40) is a topical dermatological ointment containing 40% zinc oxide, developed and manufactured by the Mexican pharmaceutical company Industria Farmacéutica Andrómaco. It is indicated for the treatment of dermatitis, minor skin wounds, eczema, and erythroderma. The product functions by creating a physical protective barrier over the skin, which helps to reduce inflammation, irritation, burning, and itching. Additionally, it provides mild antiseptic effects to help prevent secondary infections in damaged skin areas. UNNUS is approved for marketing in Mexico.
- Brand names
- UnnusUnnus 40Unnus40Unnus-40
- Other names
- zinc oxide 40% ointment
Beyond the preview
Go deeper on Unnus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unnus.